keymessage1广谱强效终稿外发.pptx

单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,#,单击此处编辑母版标题样式,#,单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,#,单击此处编辑母版标题样式,#,单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,#,单击此处编辑母版标题样式,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,#,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,#,2015,美平,Key Message,针剂产品组,DSPC-MEPM-15-05,美平,是,广谱强效的碳青霉烯,抗生素,美,平,对,革兰阴性菌敏感性高,美平,对,产,ESBL,菌所致感染的治疗成功率很高,经验,性治疗重症感染，美,平,能,迅速,控制感染,2015,美,平,Key Message,美平,Key Selling Messages,:,美平,抗菌谱广且抗菌活性高,，覆盖革兰阳性,、阴性及,厌氧菌,美平,临床疗效和细菌清除率优于,亚胺培南、头,孢及酶抑制,剂,碳青霉烯类,抗生素具有,广谱强效的特点,碳青霉烯类,抗生素具有,广谱,、强效,、对,绝大多数,内酰胺,酶高度稳定的抗菌活性,特点,，是治疗危重感染或初始抗生素治疗失败的复杂,感染,的常用抗菌药物,之一。,碳青霉烯类,抗生素在,大多数,情况下耐受性良好，不良反应发生率较低，是,一种,安全性较高的,广谱、强效,抗菌,药物。,Papp-wallace KM,et al.Antimicrob Agents Chemother 2011;55(11):4943-60,Lo TS,et al.Recent Pat Antiinfect,Drug Discov 2008;3(2):123-31,Mepem Key Selling Messages 1,:,美,平,抗菌谱,广,且抗菌活性高,，,覆盖革兰阳性,、阴性及厌氧菌,美平,的抗菌谱广,革兰氏,阳性菌,厌氧菌,革兰氏,阴性菌,美,平,美,平,覆盖革,兰阳性,菌，,MIC,90,值,和亚胺培南、帕尼培南相似,0.12,0.5,2,8,32,128,2009,年日本耐药监测,The Japanese Journal of Antibiotics.64-2.2011;Apr:53-95,美,平,覆盖,革兰阴性菌，,MIC,90,值,明显低于亚胺,培南和帕尼培南,0.008,0.03,0.12,0.5,2,8,32,2009,年日本耐药监测,The Japanese Journal of Antibiotics.64-2.2011;Apr:53-95,41,美,平,覆盖厌氧菌，,其中,梭杆菌,属,MIC90,值明显,低于亚胺,培南和帕尼培南,0.12,0.5,2,8,32,128,2009,年日本耐药监测,The Japanese Journal of Antibiotics.64-2.2011;Apr:53-95,中国美平,药敏监测,China Meropenem Susceptibility Surveillance,70%,90%/,尚可,70%/,较差,敏感率,/,抗菌活性,90%/,非常好,常见细菌,敏 感 率,（,%,）,美平,亚胺培南,头孢哌酮,/,舒巴坦,哌拉西林,/,他唑巴坦,大肠埃希菌,100,100,82.4,96.7,肺炎克雷伯菌,90.9,91.4,72.7,85奇异变形杆菌,100,100,100,100,阴沟肠杆菌,99.4,98.2,78.4,89.8,弗劳地柠檬酸杆菌,96,96,81.3,82.7,粘质沙雷菌,98.5,98.5,93.8,96.9,摩根摩根菌,100,26.2,100,100,铜绿假单胞菌,71.3,59.6,77.5,77.5,洋葱伯克霍尔德菌,88.5,鲍曼不动杆菌,36,37.8,33.1,29.1,美,平,对,革兰阴性菌覆盖广、敏感率高,CMSS 2012,王辉等,中华医学杂志,2013,Vo93.No18,1388,1396,美,平,对厌氧菌抗菌活性强，耐药率低,美平,对于,腹腔内感染致病菌,的抗菌活性,（TEST,2004-2009年,）,对革兰阴性,厌氧菌,，,抗菌活性最,强的,药物,是：,甲硝唑,、,美罗培南,（耐药范围分别为0.0-0.5和0.0-0.9,）,对,革兰阳性厌氧菌，,耐药率最低的为美罗培南,、哌拉西林,/,他唑巴坦，甲硝唑（耐药范围分别为,0.0-0.5,、,0.0-1.8,和,0.0-3.2,）,Donna,Mayne,et al.,Diagnostic Microbiology and Infectious Disease 2012,美平,治疗脆弱拟杆菌的抗菌活性不受,PH,值影响，而亚胺培南酸性增加时耐药迅速增加,Lowe,MN,Drugs.2000 Sep;60(3):619-46.,Mepem Key Selling Messages,2:,美,平,临床,疗效和细菌清除率优于,亚胺培南、头孢及酶抑制剂,全球资料荟萃分析显示美平,临床疗效,和细菌清除率优于亚胺培南,Steven J.CURRENT,MEDICAL RESEARCH AND,OPINION 2005;21(5):,785794,0.75 0.80 0.85 0.90 0.95 1.00 1.05 1.10,27,项研究,2000,例患者的荟萃分析,临床疗效,P=0.001,细菌清除率,P=0.008,不良反应,P=0.02,RR1.00,表明美平,疗效优于,亚胺培南,/,西司他丁,RR1.00,表明美平,不良反应少于,亚胺培南,/,西司他丁,美平,比亚胺培南有更卓越的临床和细菌学疗效,(,有统计学差异）,美平,比亚胺培南有更少的不良反应,(,有统计学差异）,五种抗生素比较，美平,的临床疗效和,细菌清除均具有,明显优势,混合治疗对照,MTC,2009,抗生素,OR(95,CI,）,临床疗效,细菌清除,亚胺培南,1.00,1.00,美 平,1.52(1.231.86),1.45(1.151.80),头孢吡肟,1.08(0.651.69),1.45(0.722.63),厄他培南,0.83(0.571.15),0.76(0.321.52),哌拉西林,/,他唑巴坦,0.76(0.551.00)0.83(0.471.35),Steven,J.,CURRENT MEDICAL RESEARCH AND,OPINION 2009;25(1):25161,应用,MTC,分析了,34,项临床研究，,以亚胺培南为参照,1.00,，美平,的临床疗效、细菌清除情况等都具有明显优势,总体疗效,美平,单药疗效优于头孢他啶氨基糖苷类的联合治疗,Tmt,treatment;,RR,relative risk;,CI,confidence interval.,Study,or sub-category,Tmt 1(Experimental),n/N,Tmt 2(Control),n/N,RR,值,(random),95%CI,Weight,%,RR(random),95%CI,02 Meropenem vs Ceftazidime/Aminoglycoside,Sieger 1997,30/106,43/105,55.44,0.69(0.47,1.01),Alvarez-Lerma M-2001,22/69,32/71,44.56,0.71(0.46,1.09),Subtotal(95%CI),175,176,100.00,0.70(0.53,0.93),Total events:52(Tmt 1 Experimental),75(Tmt 2control),Test for heterogeneity:Chi,2,=0.01,df=1(P=0.94),I,2,=0%,Test for overall effect;Z=2.47(P=0.01),0.5,0.7,1,1.5,2,Favours,美平,Favours,联合,Aarts MA et al.Crit Care Med 2008;36(1):108-117,0.7,RR1.00,表明美平,疗效优于,联合治疗组,The end,！,